I'm relatively new to BMOD, but see this company as having a great deal of promise. Obviously the company's financials are a mess, but they've already shown that their lung cancer assay is much more cheap and effective than any current method (according to their top line results... will have to wait and see what the published results look like). It is hard to imagine them not being granted funding of some sort given these preliminary, but very promising, results. Furthermore, they are in the process of improving the accuracy of their test while further lowering its cost.
Even assuming the method only works for lung cancer (which seems very unlikely, given that in theory the method should work for a wide variety of cancers), the company is looking at a minimum of $1 billion in revenues in 5 years after the product is on the market. I realize that FDA approval is a long and expensive process, but this product has already been shown to be both safe and effective. Assuming the pivotal trial results look anything like the pilot results (if anything they should look better, given that the company is refining the product to increase testing accuracy), approval in the U.S. and Europe seems like a foregone conclusion.
Despite all this, the stock is trading just above a penny. Am I missing something here?
